INTRODUCTION 40 41
Despite recent efforts to improve stratification of conventional chemotherapy for the 42 treatment of patients with acute myeloid leukemia (AML), survival rates remain less than 70% 43 and 40% for children and adults, respectively 3, 4 . Recent genomic profiling studies have begun 44
to reveal that AML is characterized by the predominance of mutations of genes encoding 45 regulators of gene transcription and chromatin structure 5, 6 . Indeed, most AML chromosomal 46 translocations, such as those involving MLL (KMT2A) gene rearrangements, encode chimeric 47 transcription or chromatin remodeling factors 7 . Recent functional genomic efforts have identified 48 specific molecular dependencies of aberrant AML gene expression, such as the requirement of 49 DOT1L for the maintenance of MLL-rearranged leukemias, prompting the clinical development 50 of DOT1L methyltransferase inhibitors for AML therapy 8, 9 . Similarly, additional AML subtypes 51 appear dependent on aberrant regulation of gene expression, conferring a susceptibility to 52 inhibition of CDK8 and BRD4 that in part regulate the Mediator transcriptional coactivation 53 complex 2, 10, 11 . 54
In addition, recent studies have also implicated aberrant activity of hematopoietic 55 transcription factors and their co-activators, such as MYB and CBP/P300, in recruitment of the 56 basal transcriptional apparatus in AML cells 2, 12, 13 . In particular, MYB is a sequence-specific 57 hematopoietic transcription factor that is translocated and aberrantly duplicated in a subset of T-58 cell acute lymphoblastic leukemias (T-ALL) 14, 15 . Leukemogenic activities of MYB require its 59 physical and specific association with the transcriptional co-activator CBP and its nearly 60 identical paralogue P300 12 . This interaction is associated with the recruitment of CBP/P300 and 61 its chromatin remodeling of transcriptional circuits required for leukemogenesis 16 .
62
While CBP/P300 can be inactivated by nonsense and missense mutations in a variety of 63 cancers including acute lymphoblastic leukemias 17 , both MYB and CBP/P300 are not currently 64 4 known to be mutated in AML 18 . Importantly, transient suppression of MYB expression can 65 eliminate MLL-AF9 leukemias but is dispensable for normal myelopoiesis, emphasizing its 66 specific functional requirements in AML pathogenesis 2 . In addition, the Booreana strain of mice 67 that is mutant for Myb E308G in its transcriptional activation domain and impairs the molecular 68 recognition of Myb by the KIX domain of Cbp/p300, exhibits normal hematopoiesis, but is 69 resistant to leukemogenesis induced by the MLL-AF9 and AML1-ETO oncogenes 12 . Altogether, 70 these considerations raise the possibility that blockade of aberrant transcriptional coactivation 71 by CBP/P300 and its transcription factors may be a potential therapeutic strategy in AML. 72
Previous attempts to interfere with aberrant transcriptional coactivation in AML have 73 focused on the pharmacologic blockade of lysyl acetyltransferase activities of CBP/P300 19, 20 . In 74 addition, chetomin and napthol derivatives have been identified to interfere with the protein-75 protein interactions of the MYB-CBP/P300 complex [21] [22] [23] . Here, we extended these efforts by 76 focusing on the specific requirement of MYB E308 in its transcriptional activation domain for 77 molecular recognition of the CBP/P300 KIX domain to therapeutically target and dismantle the 78 assembly of the MYB:CBP/P300 leukemogenic transcription factor-coactivator complex, as 79 hypothesized previously 1, 12, 24 . Using molecular dynamics simulations and structural analysis of 80 the MYB:CBP/P300 molecular complex, we designed a stabilized, cell-penetrant peptidomimetic 81 inhibitor of MYB:CBP/P300 binding, termed MYBMIM. Consequently, we investigated its 82 molecular and cellular activities, blockade of leukemogenic gene expression, and therapeutic 83 potential in preclinical leukemia models in vitro and in vivo. 84
Results

86
Design and binding activity of peptidomimetic MYB:CBP inhibitor MYBMIM 87
Stereoselective substitution of D-amino acids in peptides and their fusion to protein 88 transduction domains have been used to enhance their stability and intracellular delivery, 89 respectively 25, 26 . Based on the importance of the Myb E308 residue for MYB:CBP/P300 90 binding and leukemic transformation 1, 12, 24 , we reasoned that a peptide designed to compete 91 with this region of MYB might represent an effective therapeutic inhibitor. We thus developed a 92 peptide mimetic of MYB residues 293-310, based on the high-resolution structure of the 93 MYB:CBP/P300 complex ( Figure 1a ). We fused this peptide to the cationic cell-penetrant TAT 94 peptide, as optimized by Dowdy and colleagues [27] [28] [29] [30] . The peptide was designed in the retro-95 inverso orientation containing D-amino acids, and termed MYBMIM (Figure 1b , Supplementary 96 Table 1 ). Since retro-inverso strategies are able to mimic selected helical peptides 31, 32 , we used 97 molecular dynamics simulations to model the binding of the retro-inverso and native forms of 98 MYB peptides to the CBP/P300 KIX domain (Figure 1b ). This analysis revealed that the retro-99 inversion of MYB peptide stereochemistry is compatible with binding to the CBP/P300 KIX 100 domain, as evidenced by the largely complete preservation of key MYB:CBP/P300 contacts, 101 including the E308:H602 and R294:E665 salt bridges, and the L302 hydrophobic burial 102 7
135
MYBMIM suppresses transcriptional enhancers and activation in AML cells 136
MYB and CBP/P300 mediate their transcriptional co-activation effects in part through the 137 assembly and stabilization of transcription factor complexes at specific enhancers and promoter 138 elements 33, 34 . Thus, dissociation of the MYB:CBP/P300 complex by MYBMIM would be 139 expected to reduce MYB-dependent occupancy and gene trans-activation at specific target 140 genes responsible for aberrant leukemia cell growth and survival. To investigate the effects of 141 MYBMIM on gene expression in AML cells, we analyzed transcriptome profiles of MLL-142 rearranged MOLM-13 cells treated with MYBMIM as compared to TG3 control using RNA 143 sequencing (RNA-seq). We observed no significant changes in gene expression induced by 144
TG3 as compared to mock-treated cells, confirming the specificity of MYBMIM-induced effects 145 To test the prediction that MYBMIM would suppress the assembly of MYB:CBP co-154 activation chromatin complexes, we used specific chromatin factor immunoprecipitation followed 155 by DNA sequencing (ChIP-seq) to analyze genome-wide distribution of MYB protein complexes 156 in MV-411 cells treated with MYBMIM. We found that treatment with MYBMIM, but not with its 157 near-isosteric inactive TG3 analogue or untreated control, led to the elimination of 2,690 MYB 158 8 complexes bound to promoters and enhancers (Figure 3a , Supplementary Data S1). Of the total 159 5,122 MYB protein complex-bound loci, 587 were found to occur within 50 kb of the 1,730 160 significantly downregulated genes observed in coupled transcriptome analyses (Supplementary 161 Figure 2 ). In addition, we found that MYB-bound promoters and enhancers, specifically affected 162 by MYBMIM treatment as compared to TG3 or untreated controls, were significantly enriched for 163 DNA sequence motifs corresponding to MYB, ERG, SPI1/PU.1, CEBPA, and RUNX1 164 transcription factors (Supplementary Figure 3, Supplementary Table 2 ). This suggests that their 165 DNA binding may cooperate with MYB and/or CBP/P300, as suggested by prior studies 16 .
166
A key mechanism of CBP/P300 co-activation involves its acetylation of K27 of histone 3 167 (H3K27Ac), which facilitates gene trans-activation 34, 36 . To examine the effects of MYBMIM on 168 CBP/P300-associated histone acetylation, we analyzed H3K27Ac genome-wide using ChIP-seq 169 methods and noted a significant reduction in MYB-containing H3K27Ac sites by MYBMIM 170 treatment as compared to TG3 control (52% reduction, p=0.0032, median fold change). This 171 difference was in spite of the genome-wide reduction in all H3K27Ac sites (33% reduction, 172 p=0.034). There were a total of 1,479 sites with significantly decreased H3K27Ac enrichment 173 (Figure 3b ). We then focused on the enhancer at the BCL2 locus, where we observed 174 
MYBMIM induces apoptosis of AML cells in vitro 183
As AML cells require MYB:CBP/P300-dependent gene expression for growth and 184 survival, we reasoned that MYBMIM should exhibit growth suppressive effects on AML cells. 185
Using MYBMIM doses similar to the binding affinities using direct biochemical assays (Figure  186 1c), we treated a panel of AML cell lines with MYBMIM, including those with (MOLM-13 and 187 MV-411) and without MLL rearrangements (ML-2 and HL-60). We observed that MYBMIM, but 188 not its inactive congeners TG1, TG2, or TG3, induced sustained, logarithmic reduction of growth 189 of AML cell lines when compared to untreated control (p = 7.2e-7 for MOLM-13; p = 9e-6 for 190 MV-411, p = 1.7e-6 for ML-2, p = 3.3e-6 for HL-60, t-test, Figure 3a 
MYBMIM impedes human leukemia progression in mouse xenograft models in vivo 219
To investigate the potential of MYBMIM for leukemia therapy, first we analyzed the 220 effects of MYBMIM on the proliferation and differentiation of healthy human umbilical cord blood 221 (HUCB) hematopoietic progenitor cells in vitro and mouse hematopoiesis in vivo. We isolated 222
CD34
+ mononuclear HUCB cells, and assessed their self-renewal and multi-lineage 223 differentiation using clonogenic assays in methylcellulose in vitro 38 . We observed no significant 224 effects on granulocyte/macrophage and erythroid progenitors, as assessed by their morphology 225 and clonogenicity (Figures 4a and 4b ). Likewise, we observed no significant changes in 226 peripheral blood counts of C57BL/6J mice treated with MYBMIM by daily intra-peritoneal (IP) 227 injection for 7 days, as measured by the analysis of total leukocytes, lymphocytes, platelets, and To investigate the anti-leukemia efficacy of MYBMIM, we engrafted sublethally-irradiated 237 NOD-scid IL2Rγnull (NSG) mice with primary patient-derived MLL-rearranged human leukemia 238 cells, with their detailed characterization described in Supplementary Table 3 , and determined 239 leukemia development using peripheral blood flow cytometry for human-specific CD45 (hCD45). While CBP and P300 are nearly identical in structure, they have distinct and non-303 redundant functions 47 . Indeed, recent study of CBP and P300 in Nup98-Hoxd13-induced 304 leukemogenesis found that loss of p300, but not Cbp, contributes to leukemogenesis 48 . 305
Conversely, Cbp and p300 were cooperatively required for leukemogenesis induced by Nup98-306
14
Hoxa9 and Moz-Tif2 oncogenes 13 . Importantly, at least for AML1-ETO-induced leukemias, its 307 leukemogenicity is in part dependent on the acetylation of AML1-ETO by CBP/P300 49 . In 308 addition, loss-of-function mutations of CBP are present in a variety of human cancers, and 309 recent work found a functional requirement for P300 in these CBP-deficient tumors 50 . Insofar as 310 MYBMIM may affect the activities of the KIX domains of both CBP and P300, it is possible that 311 MYBMIM and its drug-like derivatives may be of therapeutic utility in CBP-deficient cancers. 312
The KIX domain of CBP/P300 recognizes a variety of protein interactors, including MYB, 313 CREB, JUN, and MLL1, which bind to it with varying affinities and partially overlapping 314 interaction surfaces, presumably leading to dynamically regulated and partially competitive 315 transcription factor assemblies 51 . Given the shared physical properties of the interaction of 316 transactivation domains of various transcription factors with the KIX domains of TAF9, MED15, 317
and CBP/P300 52 , we anticipate that similar design strategies used for MYBMIM will be useful 318 for the modulation of their assembly for biological and therapeutic purposes. Even though 319 binding affinity of MYB:CBP/P300 in a purified reconstituted interaction in vitro is on the µM 320 scale, its observed effects in cells are presumably due to the TAT-directed nuclear accumulation 321 of MYBMIM, where its extended residence time is expected to achieve specific competition of 322 the endogenous MYB:CBP/P300 complexes. While MYBMIM exhibits specific effects on the 323 binding and activity of MYB:CBP/P300 complex in AML cells, it is also possible that its effects 324 may affect MLL1 and CREB interactions with CBP/P300 53, 54 . Thus, MYBMIM offers a probe for 325 the study of CBP/P300 KIX domain function and its therapeutic targeting in cancer. water molecules, respectively, with a 5 Å buffer of water in a rectangular box. Three chloride 376 ions were added to both systems to maintain electric neutrality. The OPLS3 force field was used 377 to describe both L-and D-amino acid peptide-protein complexes 60 . For each system, a 378 relaxation phase, with a combination of Brownian dynamics and restrained molecular dynamics 379 phases was performed to equilibrate the systems. Periodic boundary conditions with a cutoff of 380 0.9 nm for both particle-mesh Ewald and Lennard-Jones interactions were used 61, 62 . Each 381 equilibrated system was then subjected to 60 ns simulations with identical parameters. 382
Simulations were performed using the constant pressure and constant temperature (NPT) 383 ensemble with a Berendsen thermostat and barostat. The equations of motion were integrated 384 using RESPA with a time step of 2.0 fs for bonded and short-range non-bonded interactions, 385 and 6.0 fs for long-range electrostatic interactions 63 . System coordinates were saved every 5 386
ps. 387 388 389
Expression and purification of recombinant CBP KIX domain 390
BL21(DE3) cells (Invitrogen) transformed with pGEX-KIX plasmid were induced at 37° C 391
with isopropyl β-D-1-thiogalactopyranoside for 3 hours. Cells were lysed in 50 mM Tris-HCl pH 392 7.3, 150 mM NaCl, 0.1% Tween-20, 1mM DTT, 5 mM EDTA, supplemented with protease 393 inhibitors described above and sonicated for ten minutes (15 sec on, 15 sec off, 40% amplitude) 394 using the Misonix probe sonicator (Qsonica, Newtown, CT). Lysate was cleared by 395 centrifugation for 1 h at 21,800 x g at 4° C. Cleared lysate was incubated with 4 mL glutathione 396 agarose resin slurry (GoldBio) for 1 h at 4° C to capture GST-KIX. Resin was washed four times 397 with 50 mM Tris-HCl pH 7.4, 150 mM NaCl. KIX domain was cleaved from GST by incubation of 398 resin-bound GST-KIX with 160 U thrombin (GE Healthcare) overnight at room temperature. 399
Resin was centrifuged at 500 x g for 5 min. Supernatant containing cleaved KIX was collected 400 and dialyzed at 4° C against 50 mM MOPS pH 6.5, 50 mM NaCl, 10% glycerol, 1 μM tris-2-401 carboxyethylphosphine. Cleaved KIX was purified using a linear gradient of 50 mM to 1 M NaCl 402 by cation exchange chromatography using MonoS 5/50 GL column (GE Healthcare). Fractions 403 containing purified KIX were dialyzed against 50 mM potassium phosphate pH 5.5, 150 mM 404 NaCl, 10 μM tris-2-carboxyethylphosphine, 30% glycerol, and stored at -80° C. 405 406 407
Microscale thermophoresis (MST) 408
Binding of purified recombinant KIX with FITC-conjugated peptides was measured using 409
Monolith NT.115 (NanoTemper Technologies). Assays were conducted in 50 mM sodium 410 phosphate, 150 mM NaCl, 0.01% NP-40, pH 5.5. FITC-conjugated peptides (FITC-MYB at 250 411 nM, FITC-MYBMIM at 500 nM, FITC-TAT at 500 nM, FITC-TG1 at 500 nm, FITC-TG2 at 500 412 nm, and FITC-TG3 at 500 nm) were mixed with 16 increasing concentrations of KIX (0.0015 to 413 50 μM, 1:1 serial dilutions) and loaded into MST Premium Coated capillaries. MST 414 measurements were recorded at room temperature for 10 sec per capillary using fixed IR-laser 415 power of 80% and LED excitation power of 40-50%. 416
417
Confocal microscopy 418
Confocal imaging was performed using the Zeiss LSM880 confocal microscope and 40X 419 objective with 1.5 µm z-stack images. Cells were applied to a poly-L-lysine-coated chambered 420
Nunc Lab-tek II coverslip and incubated for 2 hours at 37° C. FITC-conjugated MYBMIM was 421 added to cell suspensions at a concentration of 50 nM and incubated for 1 hour at 37° C. Cells 422 were counter-stained using Hoechst 33342 and Mitotracker Red CMX ROS (MProbes) for 10 423 minutes at a final dilution of 1:10,000 prior to imaging. pellets were resuspended in 1 mL of cold lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 466 0.5 mM EDTA, 1 mM DTT, 0.5% Triton X-100, 10% glycerol supplemented with protease 467 inhibitors described above) and incubated on ice for 10 min. Cells were centrifuged for 5 min at 468 2,000 x g at 4° C. Supernatant was clarified by centrifugation for 15 min at 18,000 x g at 4° C. 469 PBS with 0.5% BSA was removed from peptide-conjugated streptavidin bead slurry, lysate was 470 added to 1 mg beads, and affinity purification proceeded for 3 h at 4° C. For ChIP-seq analysis, reads were quality and adapter trimmed using 'trim_galore' 495 before aligning to human genome assembly hg19 with bwa mem using the default parameters. 496
Aligned reads with the same start position and orientation were collapsed to a single read 497 before subsequent analysis. Density profiles were created by extending each read to the 498 average library fragment size and then computing density using the BEDTools suite. Enriched 499 regions were discovered using MACS 2.0 and scored against matched input libraries. Genomic 500 'blacklisted' regions were filtered 501
(http://www.broadinstitute.org/~anshul/projects/encode/rawdata/blacklists/hg19-blacklist-502 README.pdf) and remaining peaks within 1kb were merged. Read density normalized by 503 sequencing depth was then calculated for the union of peaks, and the MYBMIM and control 504 samples were compared using Welch's t-test. 505
506
Chromatin immunoprecipitation and quantitative PCR (ChIP-PCR) 507
For H3K27Ac ChIP-PCR, MV-411 cells were treated with 20uM MYBMIM or TG3 for 12 508 hours and then cross-linked with 1% formaldehyde for 10 min at room temperature. Cross-509 linking was ended by the addition of 1/20 volume of 2.5M Glycine for 5 min at room temperature 510 followed by cell lysis and sonication (E220 Covaris sonicator) to obtain 100-to 500-bp 511 chromatin fragments. H3K27Ac Rabbit polyclonal antibody (Abcam, #4729) was conjugated to 512
Protein A and G Dynabeads per manufacturer's instructions (Thermo Fischer Scientific). 513
Lysates were incubated overnight at 4°C with antibody-conjugated beads in suspension. 514
Precipitates were then washed sequentially with cold washing solution (1% NP-40, 1mm EDTA, 515 50 mM Hepes-KOH, pH 7.6, 500 mM LiCl, 0.7% Na-Deoxycholate) and then washing solution 516 (50 mM Tris-HCL, pH 8.0, 10mM EDTA, 50mM NaCl), then eluted in elution buffer (50 mM 517
Tris-HCL, pH 8.0, 10mM EDTA, 1% SDS). Reversal of crosslinks in elution buffer overnight at 518 65°C followed by digestion of RNA and protein using RNase (Roche, Catalog No. 111119915-519 001) and Proteinase K (Roche, Catalog No. 03115828001). DNA purification was performed 520 using PureLink PCR Purification Kit per manufacturer's protocol (Invitrogen). RT-qPCR was 521 performed as described below. 522
523
RNA sequencing (RNA-seq) 524
Reads were quality and adapter trimmed using 'trim_galore' before aligning to human 525 assembly hg19 with STAR v2.5 using the default parameters. Coverage and post-alignment 526 quality were assessed using the Picard tool CollectRNASeqMetrics 527
23
(http://broadinstitute.github.io/picard/). Read count tables were created using HTSeq v0.6.1. 528
Normalization and expression dynamics were evaluated with DESeq2 using the default 529
parameters. 530 531
Cell viability analysis 532
Cells were resuspended and plated at a concentration of 2x10 5 cells in 200 µL in 96-well 533 tissue culture plates. Media with peptides was replaced every 48 hours. To assess the number 534 of viable cells, cells were resuspended in PBS and 10 µL of suspension was mixed in a 1:1 ratio 535 with 0.4 % Trypan Blue (Thermo Fisher) and counted using a hemacytometer (Hausser 536 Scientific, Horsham, PA, USA). To assess viability using an ATP-based assay, cell viability was 537 assessed using the CellTiter-Glo Luminescent Viability assay, according to the manufacturer's 538 instructions (Promega). Luminescence was recorded using the Infinite M1000Pro plate reader 539 Wilmington, MA, USA). PCR primers are listed in Supplementary Table 4 . Ct values were 568 calculated using ROX normalization using the ViiA 7 software (Applied Biosystems). 569 570
Retrovirus production and cell transduction 571
The MIG-BCL2 vector was packaged using pUMVc and pCMV-VSVG vectors in HEK 572 were plated in biological triplicates. 35x10mm dishes placed into a larger 100x15mm dish with 592 one 35x10mm dish filled with sterile water). Dishes were incubated at 37°C with 5% CO2 for 14 593 days. Both erythroid progenitor and granulocyte-macrophage progenitors were observed and 594 quantified. Brightfield microscopy CFU-Gm and BFU-E colony images were obtained using 10x 595 and 20x magnification on the Zeiss Zen observer inverted stand for live imaging. 596 597
Mouse studies 598
All mouse experiments were carried out in accordance with institutional animal protocols. 599
For toxicity studies, female C57BL/6J mice (The Jackson Laboratory, Bar Harbor, Maine, USA) 600
were treated with MYBMIM peptide suspended in PBS and administered daily through 601 intraperitoneal injection at a daily dose of 25 mg/kg for a total of 7 days. Mice were harvested at 602 the end of treatment for hematologic, biochemical and histologic analyses. The data discussed in this publication have been deposited in NCBI's Gene Expression 632
Omnibus and are accessible through GEO Series accession number GSE94242. 633
634
Statistical Analysis 635
For comparisons between two sample sets, statistical analysis of means was performed 636 using 2-tailed, unpaired Student's t-tests. Survival analysis was done using the Kaplan-Meier 637 method, as assessed using a log-rank test. For gene expression analysis, statistical significance 638 was assessed using paired t-tests. 639 
